Company intelligence / Profile preview
ADARx Pharmaceuticals
San Diego, California, United Statesadarx.com ↗
- Ownership
- Private
- Employees
- ~70
- Development stage
- Other
01
Overview
Early phase 1 clinical data for ADX-324 shows potential to be best-in-class treatment for hereditary angioedema. Pre-clinical studies in non-human primates suggest possibility for bi-annual or annual low volume subcutaneous dose regimen for ADX-324.
- Therapeutic areas
- CardiovascularMetabolic DisordersImmunologyRare DiseasesNeurology
- Modalities
- RNA therapeuticssiRNA (small-interfering RNA)
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
Beyond the preview
Go deeper on ADARx Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ADARx Pharmaceuticals.